BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:CTX-8371 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of CTX-8371\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06150664-2445@assetmemo.bio
DTSTAMP:20261121T005436Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:CTX-8371: Phase 1 readout est. (NCT06150664)
DESCRIPTION:CTX-8371\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A Phas
 e 1 of CTX-8371 in Patients With Advanced Malignancies\nEstimated primary 
 completion: December 2026. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/ctx-8371#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06150664
URL:https://assetmemo.bio/drug/ctx-8371#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
